



Justyna Mączyńska, MD, graduated from the Medical University of Warsaw in 2014, currently a cardiology resident in the 2nd Coronary Artery Disease Department, Institute of Cardiology, Warsaw, Poland. During her studies, she was actively working in the Students' Scientific Group by the 1st Department of Cardiology at Medical University of Warsaw. She is the author of several publications and abstracts presented during cardiology congresses. Her current areas of interest include thromboembolic risk stratification, atrial fibrillation, chronic heart failure, novel cardiovascular risk factors, and cardiac biomarkers.



Iwona Kurkowska-Jastrzębska, PhD, MD, neurologist and clinical pharmacologist, Head of the 2nd Department of Neurology at the Institute of Psychiatry and Neurology in Warsaw, Poland. She had been working for about 10 years in the Department of Experimental and Clinical Pharmacology of Warsaw Medical University, where she was involved in basic research of neurodegenerative processes and the role of neuroinflammatory reaction in the central nervous system. She spent a few short post-doctoral internships in the Department of Neuropathology and in the Department of Neuroimmunology of the Max Planck Institute of Psychiatry in Martinsried, Germany. Her present research interests include neuroimmunology, demyelinating diseases of the central nervous system, stroke, and epilepsy. She is a member of the Committee on Neurological Sciences of the Polish Academy of Science.



Rafał Dąbrowski, MD, PhD, cardiologist, deputy head of the 2nd Coronary Artery Disease Department, Institute of Cardiology, Warsaw, Poland. Member of the Board of the Polish Cardiac Society. Fellow of the European Society of Cardiology (ESC), member of the ESC Cardiovascular Pharmacology and Drug Therapy working group. Author/co-author of 150 original and review articles, book chapters, and 50 conference papers during ESC, ESH, and ACC congresses. Main subjects of scientific interests include: upstream therapy, risk factors and pathophysiology of atrial fibrillation; pharmacokinetics and pharmacodynamics of cardiac drugs; secondary prevention in hypertension, coronary disease, heart failure and arrhythmias; cardiovascular changes in patients with arthropathies and connective tissue diseases; therapy, rehabilitation, and quality of life of patients with heart failure.